Government Embraces AI Regulation Recommendations
On 6 October 2026, the UK government officially announced its acceptance of all 44 recommendations from the National Commission on the Regulation of Artificial Intelligence (AI) in Healthcare, which were made public on 10 September. This announcement outlines a comprehensive strategy for implementing these recommendations across the nation. In conjunction with this response, the Medicines and Healthcare products Regulatory Agency (MHRA) has initiated the application process for the third phase of AI Airlock, its regulatory sandbox designed for AI-enabled medical devices. This phase will focus on testing themes that directly reflect the Commission’s guidance.
Transforming AI Regulation in Healthcare
The Commission’s findings emphasise the necessity for an evolved regulatory approach tailored to AI technologies, advocating for a more proportionate, lifecycle-oriented framework. The government’s response commits to establishing a pioneering, agile regulatory system for AI devices that fosters innovation while ensuring patient safety and public confidence. The goal is to facilitate quicker access to safe and effective AI solutions for patients, all while maintaining stringent safeguards as these technologies advance.
A key recommendation from the Commission was the need for ongoing assessment and monitoring of AI-enabled medical devices throughout their operational lifespan, rather than relying solely on initial evaluations. The third phase of AI Airlock aims to put this principle into action by collaborating with developers, regulators, and healthcare partners to ensure that AI devices are effectively monitored and managed post-deployment. This initiative will generate valuable insights and evidence that will inform future MHRA guidance and policy. Applications for eligible developers of AI-enabled medical devices are now open, with a webinar scheduled for prospective applicants on 22 October.
Commitments to Continuous Improvement
Among the immediate actions outlined in the government’s response, the MHRA will draft new guidance by December 2026 to address the management of changes to AI-enabled devices as they evolve. This is a step towards a regulatory framework that prioritises safety while facilitating timely access to innovative solutions. Additionally, the MHRA will initiate consultations next year regarding the qualification and classification of AI-enabled devices, marking the first recommendation of the National Commission.
Other commitments include exploring new, staged authorisation pathways that permit effective AI tools to be utilised within the NHS earlier, under stringent monitoring as further real-world evidence is collected. A comprehensive implementation roadmap detailing timelines and responsibilities related to all 44 recommendations is expected to be released by Spring 2027, with regular updates on progress to follow.
Strengthening Patient Engagement and Access
The government has further pledged to collaborate with health system partners to enhance patient engagement in decision-making processes, improve access to redress in instances where care standards are not met, and ensure that the benefits of AI technologies are equitably distributed among all communities, particularly those underserved.
AI Airlock Phase 3 Now Accepting Applications
In conjunction with the government’s response, the MHRA is now accepting applications for the third phase of AI Airlock, which serves as a regulatory sandbox for AI-enabled medical devices. Following a successful pilot and Phase 2 programme, AI Airlock has secured three additional years of government funding to further its aims.
This new phase will specifically concentrate on post-market surveillance and lifecycle regulation, aligning with the pivotal themes of the Commission’s recommendations. By collaborating with tangible products and technologies, the programme aims to unite innovators, regulators, and healthcare partners to explore safe monitoring and management of AI-enabled devices throughout their operational lifespan, generating insights that will guide future MHRA policy and guidance.
Shifting Towards Lifecycle Monitoring
The government’s response, alongside the launch of AI Airlock Phase 3, signifies a pivotal shift towards ongoing, real-world monitoring of AI technologies throughout their operational life, rather than relying on isolated assessments. This approach will be complemented by new commitments to keep patients informed regarding the use of AI in their healthcare.
Health Innovation Minister James Frith expressed: “We want all patients to benefit from the life-saving potential of AI, with the confidence that it is safe, effective and properly overseen. We also want the NHS to leverage the best new technologies to provide faster, better care while allowing staff to focus more on patient needs. However, innovation must never compromise patient safety.”
Reactions from Key Stakeholders
Lawrence Tallon, Chief Executive of the MHRA, remarked that the National AI Commission has outlined a clear and ambitious framework for ensuring that the UK becomes a leader in safely delivering AI products to patients. The acceptance of the recommendations marks a significant step towards establishing a robust plan and oversight structure for their implementation.
Professor Alastair Denniston, Chair of the National Commission, expressed satisfaction with the government’s response, highlighting the importance of a people-centred approach underpinned by a regulatory system that is safe, fast, and trusted. He noted that the initiatives being prioritised in AI Airlock Phase 3 reflect this change in practice, implementing a lifecycle-based approach from the outset.
Next Steps in AI Regulation Implementation
The newly established Programme Board will convene to advance work across government, the MHRA, NHS partners, and devolved authorities on the ten priority areas identified in the government’s response. A detailed implementation roadmap is anticipated by Spring 2027, with applications for AI Airlock Phase 3 now open and the first wave of innovators expected to be selected in November 2026. A webinar for potential applicants is scheduled for 22 October.
Supporting Voices on AI Innovation
AI Minister Kanishka Narayan noted the significant potential of AI to enhance the quality of care provided by doctors and improve patient outcomes. The government’s aim is to expedite access to promising new tools, ensuring that the benefits are accessible to all citizens.
Lord Willetts, Chair of the Regulatory Innovation Office, highlighted the clarity provided by the National Commission’s vision for evolving regulation to support innovation while safeguarding patient safety and public trust. He looks forward to seeing the recommendations implemented effectively.
Steve Bates, OLS Executive Chair, welcomed the government’s commitment to a leading regulatory framework that is pro-innovation and proportionate. He emphasized the potential for these reforms to accelerate the safe development and adoption of AI technologies, benefiting patients and the wider economy.
Professor Henrietta Hughes OBE, Deputy Chair of the National Commission, reiterated the importance of patient safety, transparency, and accountability in the development of AI technologies. She commended the government’s commitment to ensure patient involvement and clear pathways to redress when necessary.
Ministers from Wales, Northern Ireland, and Scotland expressed their support for the recommendations, emphasising the importance of a regulatory framework that prioritises safety and public trust while harnessing the potential of AI to improve healthcare delivery.
Overall, the government’s acceptance of the National Commission’s recommendations represents a significant milestone in the regulation of AI in healthcare, paving the way for innovative technologies to be integrated safely and effectively into patient care.